Inventor · disambiguated record
Yi Yu
Also filed as: YU YI · YU YI-TAO
10 granted patents·14 pending applications·57 citations·filing 2006–2024
87Inventor score
Top patents by PatentIndex Score
24 records- 0196US11344609B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2021·Granted May 31, 2022·6 cites·34 claims
- 0296US11142760B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2021·Granted Oct 12, 2021·14 cites·30 claims
- 0395US11752202B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2022·Granted Sep 12, 2023·3 cites·28 claims
- 0492US11155803B2Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2020·Granted Oct 26, 2021·13 cites·30 claims
- 0587US8603457B2Nonsense suppression and genetic codon alteration by targeted modificationYU YI-TAO·Filed 2006·Granted Dec 10, 2013·18 cites·6 claims
- 0681US12016908B2Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2022·Granted Jun 25, 2024·0 cites·14 claims
- 0778US9273294B2Targeted 2′-O-methylation of telomerase non-coding RNAYU YI-TAO·Filed 2011·Granted Mar 1, 2016·3 cites·4 claims
- 0876US2024132867A1Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0970US2022235347A1Compositions and methods for treating hemoglobinopathiesBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1068US2024229030A9Nucleic acid molecules for pseudouridylationUNIV ROCHESTER·Filed 2023·Application pending·0 cites
- 1167US2025108132A1Compositions and methods for reducing complement activationBEAM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1262US11866702B2Nucleic acid molecules for pseudouridylationUNIV ROCHESTER·Filed 2019·Granted Jan 9, 2024·0 cites·24 claims
- 1358US2025170133A1Pharmaceutical combinations and methods of use of amino-pyrrolopyrimidinone compoundMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 1457US9238813B2Targeted pre-mRNA/mRNA modification and gene regulationYU YI-TAO·Filed 2013·Granted Jan 19, 2016·0 cites·19 claims
- 1555US2022170027A1Adenosine deaminase base editors and methods of using same to modify a nucleobase in a target sequenceBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1653US2023101597A1Compositions and methods for treating alpha-1 antitrypsin deficiencyBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1752US2022098593A1Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic diseaseBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1852US2022098572A1Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editorsBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1952US2022136012A1Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequenceBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2052US2020155521A1Pharmaceutical combination for treatment of cancerARQULE INC·Filed 2019·Application pending·0 cites
- 2151US2022127594A1Compositions and methods for treating glycogen storage disease type 1aBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2247US2023140953A1Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic diseaseBEAM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2342US9949981B2Compositions and methods for treating proliferation disordersARQULE INC·Filed 2015·Granted Apr 24, 2018·0 cites·20 claims
- 2434US2012021432A1Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using SameYU YI·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yi Yu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →